Introducing Tarlatamab-dlle: A New Era in Oncology Treatment
The therapy offers new hope in solid tumor treatment with fewer adverse effects.
Read More
Challenges in Adopting Novel Therapies
October 18th 2024Panelists discuss how implementing novel combination therapies or emerging agents from clinical trials into real-world clinical practice for multiple myeloma faces significant challenges, including managing complex dosing regimens, addressing potential toxicities, ensuring patient adherence, navigating insurance coverage and cost issues, and bridging the gap between highly controlled trial conditions and diverse patient populations encountered in everyday clinical settings
Read More
Real-World Considerations for New Therapies
October 18th 2024Panelists discuss how a new therapy for multiple myeloma would need to demonstrate significant improvements in efficacy, safety, or quality of life over current standards of care to warrant adoption while also considering factors such as cost-effectiveness, patient preferences, and ease of administration in their decision-making process for evaluating treatment changes.
Read More
Key End Points in Clinical Trials
October 11th 2024Panelists discuss how clinical trials in multiple myeloma can be improved to better reflect real-world scenarios and patient outcomes, emphasizing the importance of end points such as progression-free survival, overall survival, and quality of life measures, while also considering ways to increase trial inclusivity and applicability to diverse patient populations.
Read More
Impact of IFM 2009 and DETERMINATION Studies
October 11th 2024Panelists discuss how the introduction of triplet therapy prior to transplant in studies like IFM 2009 and DETERMINATION shifted the clinician mindset toward more intensive induction regimens, leading to a focus on achieving deeper responses and longer progression-free survival as primary goals of therapy for newly diagnosed multiple myeloma patients.
Read More
Treatment Regimen Considerations
October 4th 2024Panelists discuss how various patient characteristics, including age, fitness level, cytogenetic risk, and comorbidities, influence their decision to use more intensive quadruplet regimens like D-VRd (daratumumab plus bortezomib, lenalidomide, and dexamethasone) vs standard triplet regimens, such as VRd or KRd (carfilzomib, lenalidomide, and dexamethasone) in transplant-eligible multiple myeloma patients, while also considering administration logistics and supportive care requirements
Read More
Impact of Transplant Eligibility on Treatment Selection
October 4th 2024Panelists discuss how transplant eligibility significantly influences first-line treatment goals and initial therapy selection in multiple myeloma, often leading to more intensive induction regimens aimed at achieving deep remissions.
Read More
Frontline Treatment and Sequencing Therapy
September 27th 2024Panelists discuss how their institutions approach frontline treatment for transplant-eligible multiple myeloma patients, typically using a combination of novel agents like proteasome inhibitors and immunomodulatory drugs, followed by autologous stem cell transplantation and maintenance therapy, while considering factors such as patient characteristics and treatment response to guide therapy sequencing.
Read More
Treatment Landscape for Transplant-Eligible Patients with NDMM
September 27th 2024Panelists discuss how the current first-line treatment options for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM) typically involve combination therapies including proteasome inhibitors, immunomodulatory drugs, and steroids.
Read More
Impact of PD-1 and PD-L1 Expression on Overall Survival in Patients With NSCLC and Melanoma
Pharmacists play a vital role in therapy selection.
Read More
The Fludarabine Shortage and Its Ripple Effects: Navigating the Crisis
The significant surge in oncology drug shortages in 2023 particularly affected essential chemotherapeutic drugs.
Read More
Assessing Philadelphia-Like B-Cell ALL in a Largely Hispanic Population
Ph-like ALL may be predominantly prevalent in Hispanic and Latino populations.
Read More
Novel Drug Combinations in Precision Medicine Are an Emerging Landscape for Pharmacists
A single-center experience at a tertiary medical center precision medicine clinic provides insight.
Read More
USC ALL Induction Regimen Combined With Newer TKIs Is Safe, Effective for Patients With Ph+ Disease
Achieving MRD flow cytometry negativity is crucial in monitoring and predicting survival outcomes.
Read More
Real-World Efficacy, Safety of Tixagevimab/Cilgavimab in Patients With Cancer After EUA Revision
The role of monoclonal antibodies in minimizing COVID-19–related complications remains important to assess.
Read More